These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 26056042)
1. Functional intronic ERCC1 polymorphism from regulomeDB can predict survival in lung cancer after surgery. Lee SY; Hong MJ; Jeon HS; Choi YY; Choi JE; Kang HG; Jung DK; Jin C; Do SK; Yoo SS; Seok Y; Lee EB; Shin KM; Jeong JY; Lee WK; Lee J; Cha SI; Kim CH; Kim YT; Jheon S; Park JY Oncotarget; 2015 Sep; 6(27):24522-32. PubMed ID: 26056042 [TBL] [Abstract][Full Text] [Related]
2. Regulatory variants in cancer-related pathway genes predict survival of patients with surgically resected non-small cell lung cancer. Shin KM; Hong MJ; Lee SY; Jin CC; Baek SA; Lee JH; Choi JE; Kang HG; Lee WK; Seok Y; Lee EB; Jeong JY; Yoo SS; Lee J; Cha SI; Kim CH; Kim YC; Oh IJ; Na KJ; Cho S; Jheon S; Park JY Gene; 2018 Mar; 646():56-63. PubMed ID: 29289609 [TBL] [Abstract][Full Text] [Related]
3. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Takenaka T; Yano T; Kiyohara C; Miura N; Kouso H; Ohba T; Kometani T; Shoji F; Yoshino I; Maehara Y Lung Cancer; 2010 Jan; 67(1):101-7. PubMed ID: 19361884 [TBL] [Abstract][Full Text] [Related]
4. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum. Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009 [TBL] [Abstract][Full Text] [Related]
5. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports. Xu TP; Shen H; Liu LX; Shu YQ Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606 [TBL] [Abstract][Full Text] [Related]
6. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Yang Y; Xian L Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713 [TBL] [Abstract][Full Text] [Related]
7. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer. Du Y; Su T; Zhao L; Tan X; Chang W; Zhang H; Cao G PLoS One; 2014; 9(6):e99843. PubMed ID: 24933103 [TBL] [Abstract][Full Text] [Related]
8. Putative functional variants of XRCC1 identified by RegulomeDB were not associated with lung cancer risk in a Korean population. Yoo SS; Jin C; Jung DK; Choi YY; Choi JE; Lee WK; Lee SY; Lee J; Cha SI; Kim CH; Seok Y; Lee E; Park JY Cancer Genet; 2015; 208(1-2):19-24. PubMed ID: 25592768 [TBL] [Abstract][Full Text] [Related]
9. Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer. Gao H; Ge RC; Liu HY; Wang Y; Yan S Genet Mol Res; 2014 Oct; 13(4):8997-9004. PubMed ID: 25366790 [TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer. Lv H; Han T; Shi X; Yao Y; Yao Y; Qiu W; Yue L; Liang J Med Oncol; 2014 Aug; 31(8):86. PubMed ID: 24958519 [TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Isla D; Sarries C; Rosell R; Alonso G; Domine M; Taron M; Lopez-Vivanco G; Camps C; Botia M; Nuñez L; Sanchez-Ronco M; Sanchez JJ; Lopez-Brea M; Barneto I; Paredes A; Medina B; Artal A; Lianes P Ann Oncol; 2004 Aug; 15(8):1194-203. PubMed ID: 15277258 [TBL] [Abstract][Full Text] [Related]
12. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype. Tseden-Ish M; Choi YD; Cho HJ; Ban HJ; Oh IJ; Kim KS; Song SY; Na KJ; Ahn SJ; Choi S; Kim YC Respirology; 2012 Jan; 17(1):127-33. PubMed ID: 21899657 [TBL] [Abstract][Full Text] [Related]
13. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016 [TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer. Shi ZH; Shi GY; Liu LG Int J Clin Exp Pathol; 2015; 8(3):3132-7. PubMed ID: 26045829 [TBL] [Abstract][Full Text] [Related]
15. Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy. Zhang R; Jia M; Xue H; Xu Y; Wang M; Zhu M; Sun M; Chang J; Wei Q Sci Rep; 2017 Sep; 7(1):10702. PubMed ID: 28878296 [TBL] [Abstract][Full Text] [Related]
16. Intronic variant of EGFR is associated with GBAS expression and survival outcome of early-stage non-small cell lung cancer. Hong MJ; Lee SY; Choi JE; Kang HG; Do SK; Lee JH; Yoo SS; Lee EB; Seok Y; Cho S; Jheon S; Lee J; Cha SI; Kim CH; Park JY Thorac Cancer; 2018 Aug; 9(8):916-923. PubMed ID: 29806744 [TBL] [Abstract][Full Text] [Related]
17. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182 [TBL] [Abstract][Full Text] [Related]
18. Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer. Huang SJ; Wang YF; Jin ZY; Sun JY; Guo ZL Tumour Biol; 2014 May; 35(5):4023-9. PubMed ID: 24370899 [TBL] [Abstract][Full Text] [Related]
19. Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients. Grenda A; Błach J; Szczyrek M; Krawczyk P; Nicoś M; Kuźnar Kamińska B; Jakimiec M; Balicka G; Chmielewska I; Batura-Gabryel H; Sawicki M; Milanowski J Cancer Med; 2020 Jan; 9(2):605-614. PubMed ID: 31797573 [TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]